PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF ALZHEIMERS DISEASE CONTAINING N-((1-(2-(4-(2-CHLOROBENZOYL)PIPERAZINE-1-YL)ETHYL)PYRROLIDINE-(3R)-YL-CARBOMOYL)-METHYL)-3-TRIFLUOROMETHYLBENZAMIDE
A pharmaceutical composition containing N-((1-(2-(4-(2-chlorobenzoyl)piperazine-1-yl)ethyl)pyrrolidine-(3r)-yl-carbomoyl)-methyl)-3-trifluoromethylbenzamide (YJC-10592) of the present invention increase a cholinergic nervous system function and a recognition and memorizing function in an animal model with Alzheimers disease, and controls the generation of oxidation stress and amyloid plaque. The YJC-1059 improves GPx activity in the animal model with Alzheimers disease, and the GPx activity improvement is proved to be a major mechanism for the YJC-1059. The pharmaceutical composition has prevention and treatment effects on Alzheimers disease by containing the YJC-10592. 1020130143366COPYRIGHT KIPO 2014[Reference numerals] (AA) Pharmacological effect of YJC-10592 affecting the generation of amyloid plaque in hippocampus cells of APPswe/PS1dE9 dual expression mice, each value means 짹 standard error of 6 mice ^#P < 0.05, ^##P < 0.01 vs. Vehicle (one-way ANOVA, evaluate PLSD of Fisher by post testingN-{[1-(2-(4-(2-클로로벤조일)피페라진-1-일)에틸)피롤리딘-(3R)-일-카바모일]-메틸}-3-트리플루오로메틸베즈아미드 (YJC-10592)를 함유하는 본 발명의 약제학적 조성물은 알츠하이머병의 동물모델에서 인지기억능과 콜린성 신경계 기능을 유의하게 항진시키고, 산화적 스트레스 및 아밀로이드 플라크생성을 억제한다. 또한, YJC-10592는 알츠하이머병의 동물모델에서 GPx 활성을 항진시켰으며, 이것이 주요 작용기전임을 증명하였다. 따라서, 본 발명의 약제학적 조성물은 조성물에 포함된 YJC-10592에 의해 알츠하이머병의 치료 및 예방 효과를 나타낼 수 있다.
